Disease Diagnosis TRIZ Cases

Quantify 20 proteins in fresh poultry feces or intestinal content to identify gut damage and inflammation without invasive sampling.

Blood protein biomarkers paired with MRI can reveal BBB permeability and brain-tract damage when CT misses mild TBI.

Blast-flag-aware MDW cutoffs improve sepsis assessment when immature cells distort monocyte volume measurements.

Combines mTORC1 and MDK targeting to address resistance and tumor heterogeneity in TSC-associated AML and LAM.

See how immunofluorescent markers and cell morphology identify CECs in non-enriched blood for sensitive MI classification.

A multiplex panel targeting GMNN, KLHDC8A, MAPRE1, NUP50, and SKIL supports Ro-negative Sjögren’s diagnosis without lip biopsy.

Lectins recognizing fucose α1-2 galactose groups label rare respiratory cancer stem cells for earlier detection and characterization.

Enzymatic pseudodeficiencies can cause false positives; 13-biomarker UHPLC-MS/MS profiling of plasma and dried blood spots enables rapid disease differentiation.

Blood-based MMP9 and PAPP-A2 testing supports first-trimester risk assessment when cervical ultrasound measurements are inconsistent.

Existing therapies target plasma-cell dyscrasia but not deposits; these antibodies bind misfolded lambda chains to promote amyloid clearance.

Visual examination lacks accuracy and depends on provider expertise; multiplex p16 and EGFR saliva testing enables rapid quantitative point-of-care risk assessment.

TNF-α, IL-9, and IL-5 biomarkers support non-invasive AIN diagnosis across urine, saliva, or blood, reducing reliance on kidney biopsy.

Renal associated protein testing before therapy identifies likely responders and non-responders, improving selection of reno-protective treatment for kidney decline.

Measuring small-intestine microvillus length helps identify likely responders before IBD therapy, reducing trial-and-error treatment selection.

Multiplexed fluorescence labeling and digital image analysis quantify tissue biomarkers to reduce observer variation in Barrett’s progression risk assessment.

A segmented autoantibody panel distinguishes healthy, intermediate, and unhealthy states in older adults despite biomarker false-discovery challenges.

Nuclear staining and morphology identify mitotic CTCs, improving tumor grading and patient stratification beyond simple cell counts.

Urinary ALB, ORM1, serotransferrin, and TFF measurements support non-invasive CKD and glomerulopathy screening while tracking treatment response.

Combining EC4d, BC4d, and ANA levels in a logistic risk score addresses variable SLE symptoms and limited marker specificity.

Serum BCMA detection with ELISA or lateral flow assays supports non-invasive monitoring of breast cancer progression and treatment response.

Conventional blood markers lack specificity; lectin-based detection of exosome fucosylation supports accurate cholangiocarcinoma diagnosis and prognosis.

Measuring drebrin A in cerebrospinal fluid or other biological samples supports earlier, objective staging before cognitive symptoms appear.

Multiplex fluorescence imaging and multivariable scoring address observer variation and limited biomarkers in Barrett’s progression risk.

Using proADM, proBNP, and proANP levels, this case stratifies heart-failure patients for remote management and avoids unnecessary care costs.

A recombinant polypeptide-coated carrier detects EXT1/EXT2 autoantibodies in blood, helping identify autoimmune MN when PLA2R testing is negative.